Trending:
The board of directors at Gilead Sciences has announced it has chosen Daniel O’Day, the current CEO of Roche Pharmaceuticals and member of the Roche Group’s corporate executive committee, as...
The Coalition for Epidemic Preparedness Innovations (CEPI) in Norway and Imperial College London have formed an alliance to develop new vaccines against known as well as unknown pathogens, which are...
The Delaware Supreme Court in the US has ruled that German health care company Fresenius could legally back out of its acquisition of US-based Akorn.
Merck has signed an agreement to licence Canada-based Cyclica’s cloud-based in-silico proteome screening platform called Ligand Express to support its research efforts.
After two years of planning, UK-based pharmaceutical company Mallinckrodt has announced plans to split its speciality generics and active pharmaceutical ingredients (APIs) business, in addition to the drug amitiza (lubiprostone),...
GlaxoSmithKline (GSK) has agreed to acquire US-based cancer treatment developer Tesaro for $5.1bn.
Australia-based SUDA Pharmaceuticals and Zelda Therapeutics have signed a feasibility and option agreement to develop a medical grade cannabinoid oral spray.
Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project.
British pharmaceutical company Mereo BioPharma Group has announced a proposal to merge with US-based drugmaker OncoMed Pharmaceuticals.
Following advice from an independent data monitoring committee, biopharma company AbbVie has ceased enrolment in its TAHOE trial evaluating Rovalpituzumab Tesirine (Rova-T) as a second line therapy for patients with...
